By treating model governance as a proactive, integral part of operations rather than a box to check after the fact, life sciences organizations can uphold compliance, better allocate their resources, and gain a competitive edge.
Months after 23andMe CEO Anne Wojcicki publicly stated she wants to take the company she co-founded private, all of the company’s independent board directors have resigned. The board letter to Wojcicki stated that its members preferred resigning over continuing to have a difference of view over the direction of the company.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
CEO Bill Anderson said despite prior cost-cutting measures, Bayer still has too many layers of management and bureaucracy. A new restructuring will come with layoffs but the corporate shakeup plan does not yet include a separation of Bayer’s business units.
Every lawyer knows that, in a courtroom, one should never ask a question one does not know the answer to. The same holds true for a CEO holding a board meeting. Preparation, such as holding one-on-one meetings with board members ahead of the event, is essential.
As part of the second annual HLTH conference October 27-30 at the MGM Grand in Las Vegas will be a set of programming focused on how to get more women into the boardroom and leadership roles in healthcare and life sciences.
Next to family and/or significant others, no other relationship is likely to have as big an impact on the management team’s quality of life as the one with the company’s board.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Many investors and outsiders view the caliber of the board as a proxy for company quality. The validation that comes with respected board members means other investors are far more likely to consider investing in your business.
As someone who invests in small companies where the culture is really, really important to outcome, it is something I think about almost all of the time when I perform diligence on companies and sit on their boards.
I have seen how difficult it is for even very skilled, very qualified women to get placed on a board, and it has renewed my commitment to being an ally in this fight for gender diversity.